Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Inflammasome Proteins as Biomarkers of MS

Front Neurol; ePub 2018 Mar 19; Keane, et al

Recent data suggest that 2 inflammasome proteins could be potential candidate biomarkers for the onset of multiple sclerosis (MS). In this study, researchers analyzed serum samples from 32 patients with MS and 120 age-matched controls. They provided receiver operator characteristic (ROC) curves with associated confidence intervals following analyses of serum samples from patients with MS, most of which had the relapsing-remitting form of the disease, and from healthy unaffected donors, and determined the sensitivity and specificity of inflammasome proteins as biomarkers of MS. They found:

  • Caspase-1 (1.662 ± 0.6024 difference between means), apoptosis-associated speck-like protein containing an ASC (407.5 ± 35.79), and interleukin (IL)-18 (78.53 + 17.86) were elevated in the serum of MS patients when compared to controls.
  • Interestingly, the levels of IL-1β (−0.5961 ± 0.265) were lower in the MS cohort.
  • Importantly, the area under the curve (AUC) for ASC and caspase-1 were 0.9448 and 0.848, respectively.

Keane RW, Dietrich WD, de Rivero Vaccari JP. Inflammasome proteins as biomarkers of multiple sclerosis. [Published online ahead of print March 19, 2018]. Front Neurol. doi:10.3389/fneur.2018.00135.